(Total Views: 723)
Posted On: 06/25/2017 11:28:18 PM
Post# of 416

Could this be the week?
LOS ANGELES, CA--(Marketwired - Dec 19, 2016) - Endonovo Therapeutics, Inc. ( OTCQB : ENDV ) ("Endonovo" or the "Company"
"The Company had previously announced receiving a term sheet for $5 million in preferred financing from a strategic healthcare investor to develop a pipeline in vascular diseases, peripheral artery disease and ischemia/reperfusion injury. The $5 million proposed financing is part of a larger $15 million round of financing to uplist the Company's common stock onto a national stock exchange in the first half of 2017".
LOS ANGELES, CA--(Marketwired - Dec 19, 2016) - Endonovo Therapeutics, Inc. ( OTCQB : ENDV ) ("Endonovo" or the "Company"

"The Company had previously announced receiving a term sheet for $5 million in preferred financing from a strategic healthcare investor to develop a pipeline in vascular diseases, peripheral artery disease and ischemia/reperfusion injury. The $5 million proposed financing is part of a larger $15 million round of financing to uplist the Company's common stock onto a national stock exchange in the first half of 2017".


WORDS TO LIVE BY:
Never argue with stupid people, they will drag you down to their level and then beat you with experience.
Get .... PrivacyLok https://cyberidguard.com/
Try SafeVchat: https://cyberidguard.com/
My comments are only my opinion and are not to be used for investment advice.
Please conduct your own due diligence before choosing to buy or sell any stock.
Never argue with stupid people, they will drag you down to their level and then beat you with experience.
Get .... PrivacyLok https://cyberidguard.com/
Try SafeVchat: https://cyberidguard.com/
My comments are only my opinion and are not to be used for investment advice.
Please conduct your own due diligence before choosing to buy or sell any stock.
